Search Results - "Ramírez, Santiago Viteri"

Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions by Villatoro, Sergio, Mayo‐de‐las‐Casas, Clara, Jordana‐Ariza, Núria, Viteri‐Ramírez, Santiago, Garzón‐Ibañez, Mónica, Moya‐Horno, Irene, García‐Peláez, Beatriz, González‐Cao, María, Malapelle, Umberto, Balada‐Bel, Ariadna, Martínez‐Bueno, Alejandro, Campos, Raquel, Reguart, Noemí, Majem, Margarita, Blanco, Remei, Blasco, Ana, Catalán, María J., González, Xavier, Troncone, Giancarlo, Karachaliou, Niki, Rosell, Rafael, Molina‐Vila, Miguel A.

“…Many advanced cases of cancer show central nervous system, pleural, or peritoneal involvement. In this study, we prospectively analyzed if cerebrospinal fluid…”
Get full text

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts by Carbone, David, Sharpnack, Michael, He, Kai, Butterfield, Lisa H., Eggermont, Alexander M. M., Gonzalez-Cao, Maria, Karachaliou, Niki, Crespo, Guillermo, Aldeguer, Erika, Drozdowskyj, Ana, Giménez-Capitán, Ana, Teixidó, Cristina, Molina-Vila, Miguel Angel, Ramírez, Santiago Viteri, Algarra, Salvador Martin, Pérez-Ruiz, Elisabeth, Márquez-Rodas, Iván, Rodriguez-Abreu, Delvys, Blanco, Remei, Puértolas, Teresa, Royo, Maria Angeles, Rosell, Rafael, Ascierto, Maria Libera, Hamm, Svetlana, Wulff, Tanja, Kronthaler, Kerstin, Schrepfer, Sabine, Parnitzke, Ulrike, Bretz, Anne Catherine, Baumgartner, Roland, Ferrucci, Veronica, Pennino, Francesco Paolo, Dassi, Luisa, Asadzadeh, Fatemeh, Siciliano, Roberto, Carotenuto, Marianeve, Spano, Daniela, Chiarolla, Cristina Maria, Greco, Adelaide, Cantile, Monica, Di Bonito, Maurizio, Botti, Gerardo, Jonathan, Vandenbussche, Kris, Gevaert, Zollo, Massimo, Amaral, Teresa, Tampouri, Ioanna, Keim, Ulrike, Eigentler, Thomas, Garbe, Claus, Forschner, Andrea, Cesano, Alessandra, Warren, Sarah, Moogk, Duane, Li, Kaitao, Yuan, Zhou, Zhong, Shi, Yu, Zhiya, Liadi, Ivan, Rittase, William, Fang, Victoria, Dougherty, Janna, Perez-Garcia, Arianne, Osman, Iman, Varadarajan, Navin, Restifo, Nicholas P., Frey, Alan, Zhu, Cheng, Krogsgaard, Michelle, Vanpouille-Box, Claire, Formenti, Silvia C., Demaria, Sandra, Nigro, Cristiana Lo, Renziehausen, Alexander, Tzakos, Andreas G., Wang, Hexiao, Rao, Bhavya, Matin, Rubeta, Harwood, Catherine, Vivenza, Daniela, Tonissi, Federica, Occelli, Marcella, Weir, Lynda, Li, Su, Sim, Van Ren, O’Neill, Kevin, Evans, Alan, Thompson, Alastair, Szlosarek, Peter, Fleming, Colin, Proby, Charlotte, Syed, Nelofer, Merlano, Marco, Crook, Tim, Ferguson, Robert, Simpson, Danny, Martinez, Carlos, Vogelsang, Matjaz, Kazlow, Esther, Wilson, Melissa

Get full text

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study by Ou, Sai-Hong Ignatius, Ahn, Jin Seok, De Petris, Luigi, Govindan, Ramaswamy, Yang, James Chih-Hsin, Hughes, Brett, Lena, Hervé, Moro-Sibilot, Denis, Bearz, Alessandra, Ramirez, Santiago Viteri, Mekhail, Tarek, Spira, Alexander, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N, Monnet, Annabelle, Zeaiter, Ali, Kim, Dong-Wan

“…Crizotinib confers improved progression-free survival compared with chemotherapy in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer…”
Get full text

Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients by Malapelle, Umberto, Mayo de-Las-Casas, Clara, Rocco, Danilo, Garzon, Monica, Pisapia, Pasquale, Jordana-Ariza, Nuria, Russo, Maria, Sgariglia, Roberta, De Luca, Caterina, Pepe, Francesco, Martinez-Bueno, Alejandro, Morales-Espinosa, Daniela, González-Cao, María, Karachaliou, Niki, Viteri Ramirez, Santiago, Bellevicine, Claudio, Molina-Vila, Miguel Angel, Rosell, Rafael, Troncone, Giancarlo

Get full text

Efficacy and safety of the ALK inhibitor alectinib in ALK + non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673) by Ou, Sai-Hong Ignatius, Ahn, Jin Seok, De Petris, Luigi, Govindan, Ramaswamy, Yang, James Chih-Hsin, Hughes, Brett Gordon Maxwell, Lena, Hervé, Moro-Sibilot, Denis, Bearz, Alessandra, Ramirez, Santiago Viteri, Mekhail, Tarek, Spira, Alexander I., Zeaiter, Ali Hassan, Bordogna, Walter, Balas, Bogdana, Golding, Sophie, Morcos, Peter N., Kim, Dong-Wan

“…Abstract only…”
Get full text

Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report by de las Casas, Clara Mayo, Gonzalez-Cao, Maria, Ramirez, Santiago Viteri, Ariza, Nuria Jordana, Balada, Ariadna, Garzón, Mónica, Teixidó, Cristina, Karachaliou, Niki, Morales-Espinosa, Daniela, Molina-Vila, Miguel Ángel, Rosell, Rafael

“…Genomic analysis of circulating tumor DNA (ctDNA) released from cancer cells into the bloodstream has been proposed as a useful method to capture dynamic…”
Get full text

Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform by Mayo de Las Casas, Clara, Garzón-Ibañez, Mónica, Jordana-Ariza, Núria, Viteri-Ramírez, Santiago, Moya-Horno, Irene, Karachaliou, Niki, Yeste, Zaira, Campos, Raquel, Villatoro, Sergi, Balada-Bel, Ariadna, García-Peláez, Beatriz, Reguart, Noemí, Teixidó, Cristina, Jantús, Eloisa, Calabuig, Silvia, Aguado, Cristina, Giménez-Capitán, Ana, Román-Lladó, Ruth, Pérez-Rosado, Ana, Catalán, Maria José, Bertrán-Alamillo, Jordi, García-Román, Silvia, Rodriguez, Sonia, Alonso, Lidia, Aldeguer, Erika, Martínez-Bueno, Alejandro, González-Cao, Maria, Aguilar Hernandez, Andrés, Garcia-Mosquera, Juan, de Los Llanos Gil, Maria, Fernandez, Manuel, Rosell, Rafael, Molina-Vila, Miguel Ángel

“…In a significant percentage of advanced non-small cell lung cancer (NSCLC) patients, tumor tissue is unavailable or insufficient for genetic analyses at time…”
Get full text

Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification ( MET amp) detected by liquid biopsy (LBx) by Le, Xiuning, Paz-Ares, Luis, Van Meerbeeck, Jan, Viteri Ramirez, Santiago, Cabrera Galvez, Carlos, Vicente Baz, David, Kim, Young-Chul, Kang, Jin-Hyoung, Stroh, Christopher, Juraeva, Dilafruz, Bruns, Rolf, Otto, Gordon, Johne, Andreas, Paik, Paul K.

“…9121 Background: Tepotinib, a potent, highly selective, oral, MET inhibitor, showed meaningful activity in patients (pts) with NSCLC with high-level METamp by…”
Get full text

Prognostic factors of overall survival (OS) in non-small cell lung cancer (NSCLC) patients after failure on immune checkpoint inhibitors (IO) treated with anticancer vaccine OSE2101 or chemotherapy (CT) in phase 3 ATALANTE-1 randomized trial by Besse, Benjamin, Felip, Enriqueta, Campelo, Rosario Garcia, Cobo, Manuel, Mascaux, Celine, Madroszyk, Anne, Cappuzzo, Federico, Hilgers, Werner, Romano, Giampiero, Denis, Fabrice, Viteri Ramirez, Santiago, Debieuvre, Didier, Razaq, Mohammad, Schuette, Wolfgang, Zer, Alona, Attali, Pierre, Montestruc, François, Vasseur, Berangere, Dziadziuszko, Rafal, Giaccone, Giuseppe

“…e21037 Background: OSE2101 (Tedopi) is an anticancer vaccine that has shown an improvement in overall survival (OS) compared with Chemotherapy (CT) (HR 0.59; p…”
Get full text

Neratinib efficacy in a subgroup of patients with EGFR exon 18 - mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: Findings from the SUMMIT basket trial by Goldman, Jonathan Wade, Viteri Ramirez, Santiago, Mahipal, Amit, Suga, Jennifer Marie Marie, Eli, Lisa DeFazio, Lalani, Alshad S., Bryce, Richard, Xu, Feng, Shah, Naisargee, Kabbinavar, Fairooz, Boni, Valentina, Haley, Barbara B.

“…Abstract only 9068 Background: The phase 2 SUMMIT basket trial (NCT01953926) demonstrated efficacy of neratinib in patients with EGFR exon 18-mutant NSCLC…”
Get full text

Quality of life (QoL) of OSE2101 in patients with HLA-A2+ non–small cell lung cancer (NSCLC) after failure to immune checkpoint inhibitors (IO): Final data of phase 3 Atalante-1 randomized trial by Besse, Benjamin, Campelo, Rosario Garcia, Cobo-Dols, Manuel, Quoix, Elisabeth Anne, Madroszyk, Anne, Felip, Enriqueta, Cappuzzo, Federico, Denis, Fabrice, Hilgers, Werner, Romano, Giampiero, Debieuvre, Didier, Galetta, Domenico, Baldini, Editta, Viteri Ramirez, Santiago, Phan, Minh Duc, Schuette, Wolfgang, Zer, Alona, Vasseur, Berangere, Dziadziuszko, Rafal, Giaccone, Giuseppe

“…9094 Background: OSE2101 (Tedopi) is an anticancer vaccine increasing overall survival (OS) versus Standard of Care (SoC docetaxel or pemetrexed) in HLA-A2+…”
Get full text

Abstract 809: nCounter for detection of clinically relevant alterations in exosomes of non-small cell lung cancer cells and patients by Capitán, Ana Giménez, Bracht, Jill, Huang, Chung-Ying, Teixidó, Cristina, Reguart, Noemí, Boykin, Rich, Warren, Sarah, Beechem, Joseph M, Ramirez, Santiago Viteri, García, Juan José, Aguilar, Andrés, Costa, Rafael Rosell, Gerlach, Jay, Molina-Vila, Miguel Angel

“…Background: ALK, ROS1 and RET fusions and MET exon 14 skipping variant (METex14) are present in 10-15% of advanced non-small-cell lung cancer (NSCLC) patients…”
Get full text

Abstract 409: A pre-treatment plasma extracellular vesicle-mRNA signature associates with checkpoint inhibitor pneumonitis in lung cancer patients by Bracht, Jillian Wilhelmina, Viteri-Ramirez, Santiago, Aguilar, Andrés, Calabuig-Fariñas, Silvia, García-Mosquera, Juan José, Huang, Chung-Ying, Duréndez-Sáez, Elena, Potie, Nicolas, Aldeguer, Erika, Gimenez-Capitán, Ana, Rodriguez, Sonia, Roman, Ruth, Aguado, Cristina, Warren, Sarah, Camps, Carlos, Rosell, Rafael, Jantus-Lewintre, Eloisa, Molina-Vila, Miguel-Angel, González-Cao, Maria

“…Introduction: Immune checkpoint inhibitors (ICIs) have demonstrated clinical efficacy in non-small cell lung cancer (NSCLC) patients (p). However, ICIs can…”
Get full text

Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform by Giménez-Capitán, Ana, Bracht, Jillian, García, Juan José, Jordana-Ariza, Núria, García, Beatriz, Garzón, Mónica, Mayo-de-Las-Casas, Clara, Viteri-Ramirez, Santiago, Martinez-Bueno, Alejandro, Aguilar, Andrés, Sullivan, Ivana-Gabriela, Johnson, Eric, Huang, Chung-Ying, Gerlach, Jay L, Warren, Sarah, Beechem, Joseph M, Teixidó, Cristina, Rosell, Rafael, Reguart, Noemí, Molina-Vila, Miguel A

“…With the advent of precision oncology, liquid biopsies are quickly gaining acceptance in the clinical setting. However, in some cases, the amount of DNA…”
Get full text

Targeting HER2 ( ERBB2 ) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT ‘basket’ trial by Harding, James J., Cleary, James M., Quinn, David I., Braña, Irene, Moreno, Victor, Borad, Mitesh J., Loi, Sherene, Spanggaard, Iben, Park, Haeseong, Ford, James M., Arnedos, Monica, Stemmer, Salomon M., De La Fouchardiere, Christelle, Viteri Ramirez, Santiago, Fountzilas, Christos, Zhang, Jie, Xu, Feng, Lalani, Alshad S., Piha-Paul, Sarina Anne, Abou-Alfa, Ghassan K.

“…Abstract only 320 Background: Genomic profiling studies have reported somatic HER2 mutations in ~2–5% of biliary tract cancers (BTC). Clinical data from the…”
Get full text

Tracking plasma KRAS mutations (mu) in lung adenocarcinoma (LUAC) patients (p) and branching evolution by Bracht, Jillian, Karachaliou, Niki, Lanman, Richard B., Dix, Daniel, Faull, Iris, Nagy, Rebecca, López, Noemí, Palmero, Ramon, Viteri Ramirez, Santiago, Majem, Margarita, Taus, Alvaro, Carcereny Costa, Enric, Garde, Javier, Riva, Francois, Malfettone, Andrea, Sampayo, Miguel, Drozdowskyj, Ana, Felip, Enriqueta, Rosell, Rafael

“…Abstract only 9055 Background: KRAS m in LUAC p are recalcitrant to therapy. In mice models and p, STK11 m confer poor prognosis. Patients with KRAS, or KRAS…”
Get full text

Abstract 5594: Inmune gene expression by nCounter in mucinous adenocarcinoma lung cancer by Lladó, Ruth Román, Esteban, Cristina Aguado, Giménez-Capitán, Ana, Daisuke, Ueda, Ito, Masaoki, Tsutani, Yasuhiro, Miyata, Yoshihiro, Teixidó, Cristina, Reguart, Noemí, Okada, Morihito, Rodríguez, Sonia, Balada, Ariadna, Aldeguer, Erika, Ramirez, Santiago Viteri, Cao, Maria Gonzalez, Aguilar, Andrés, Rosell, Rafael, Vila, Miguel Angel Molina

“…Introduction: Although immune checkpoint inhibitors have become a standard of care for multiple cancer types; currently used biomarkers, such as PD-L1…”
Get full text

Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with MET ex14 skipping by Le, Xiuning, Felip, Enriqueta, Veillon, Remi, Sakai, Hiroshi, Cortot, Alexis B., Garassino, Marina Chiara, Mazieres, Julien, Viteri Ramirez, Santiago, Senellart, Helene, Van Meerbeeck, Jan, Reinmuth, Niels, Conte, Pier Franco, Kowalski, Dariusz, Cho, Byoung Chul, Straub, Josef, Scheele, Jürgen, Juraeva, Dilafruz, Bruns, Rolf, Heymach, John, Paik, Paul K.

“…Abstract only 9556 Background: Preliminary tepotinib data showed durable activity in pts with NSCLC with METex14 skipping prospectively identified by liquid…”
Get full text

Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC) by Park, Keunchil, John, Thomas, Kim, Sang-We, Lee, Jong Seok, Shu, Catherine A., Kim, Dong-Wan, Viteri Ramirez, Santiago, Spira, Alexander I., Sabari, Joshua K., Han, Ji-Youn, Trigo, Jose Manuel, Lee, Chee Khoon, Lee, Ki Hyeong, Girard, Nicolas, Lorenzini, Patricia A, Xie, John, Roshak, Amy, Thayu, Meena, Knoblauch, Roland Elmar, Cho, Byoung Chul

“…Abstract only 9512 Background: EGFR exon20ins-mutated NSCLC is generally refractory to EGFR tyrosine kinase inhibitors (TKIs) and is associated with poor…”
Get full text

Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies by Brahmer, Julie R., Johnson, Melissa Lynne, Dols, Manuel Cobo, Viteri Ramirez, Santiago, Coves, Juan, Sukari, Ammar, Awad, Mark M., Salgia, Ravi, Papadimitrakopoulou, Vassiliki, Rajan, Arun, Allred, Alicia Jones, Wade, Mark, Mason, Gary, Zudaire, Enrique, Knoblauch, Roland Elmar, Stone, Nicole L., Lorenzi, Matthew V., Hassan, Raffit

“…Abstract only 9093 Background: The immunogenicity, safety, and efficacy of JNJ-757, a live attenuated, double-deleted Listeria monocytogenes-based…”
Get full text